Heart disease kills more people than any other cause as many of the risks factors that contribute to it remain on the rise, ...

By Arasu Kannagi Basil (Reuters) -Drug developer Maze Therapeutics said on Monday it was targeting a valuation of up to $728.1 million in its New York initial public offering, set to be the first U.S.

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its fourth quarter and full year 2024 financial results on Monday, February 10, 2025 after the financial markets close. The company will ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...